Opsens Announces Terms Of $8 Million Equity Financing

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Opsens Inc. Announces Terms of $8 Million Equity Financing

QUEBEC CITY, QUEBEC--(Marketwired - Feb. 3, 2014) - Opsens Inc. (TSX VENTURE:OPS) (the “Company” or “Opsens”) is pleased to announce that in connection with its previously announced public offering, it has entered into an underwriting agreement with a syndicate of underwriters led by RBC Capital Markets and including Paradigm Capital Inc. (collectively, the “Underwriters”) to sell 6,164,300 common shares (the “Common Shares”) of the Company at a price of $0.73 per Common Share for aggregate gross proceeds of $4.5 million and 4,666,800 units of the Company (the “Units”) at a price of $0.75 per Unit for aggregate gross proceeds of $3.5 million (the “Offering”).

Each Unit consists of one common share in the capital stock of Opsens and one-half of one common share purchase warrant, with each whole common share purchase warrant entitling the holder thereof to purchase one common share at a price of $1.05 within 24 months from the initial closing date of the Offering.

The Company has also granted the Underwriters an option to cover over-allotments and for market stabilization purposes (the “Over Allotment Option”), which will allow the Underwriters to purchase up to an additional 924,645 Common Shares and up to an additional 700,020 Units. The Over Allotment Option may be exercised at any time up to 30 days following the closing of the Offering.

The Company intends to use the net proceeds of the Offering to prepare the commercialization and marketing strategy of its Fractional Flow Reserve (“FFR”) products, to fund research and product development and to fund its working capital. The Company will file a final prospectus in each of the provinces of Québec, Ontario, Alberta and British Columbia in connection with the Offering. Such prospectus will be available on SEDAR at www.sedar.com.

The Offering is expected to close on or about February 18, 2014 and is subject to certain customary conditions and regulatory approvals.

This press release does not constitute an offer of securities for sale in the United States or to “U.S. persons” (“U.S. persons”), as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities being offered have not been, nor will be, registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from such registration requirements.

About Opsens Inc. (www.opsens.com)

Focusing on two main growth markets, FFR in medical instrumentation and oil and gas, Opsens develops, manufactures and installs systems to measure pressure and temperature as well as other parameters using fiber optic sensing technologies. These systems are designed around patented technologies that are effective and durable in extreme conditions.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Opsens Inc.
Thierry Dumas, CPA, CA
Chief Financial Officer
418.682.9996

Opsens Inc.
Louis Laflamme, CPA, CA
Chief Executive Officer
418.682.9996
www.opsens.com

Help employers find you! Check out all the jobs and post your resume.